A 48-year-old woman with newly diagnosed type 2 diabetes (fasting blood glucose 186 mg/dL, HbA1c 9.2%) is started on a sulfonylurea. After 3 weeks, she develops severe hyponatremia (Na+ 118 mEq/L) with euvolemia and normal renal function. Which investigation is most appropriate to confirm the suspected adverse effect?

Explanation

## Clinical Presentation Analysis The patient presents with: - **Acute hyponatremia** (Na+ 118 mEq/L) within 3 weeks of sulfonylurea initiation - **Euvolemia** (no edema, normal BP, no orthostasis) - **Normal renal function** (creatinine not elevated) - **Temporal relationship** to sulfonylurea (chlorpropamide or tolbutamide most common culprits) This clinical picture is pathognomonic for **Syndrome of Inappropriate Antidiuretic Hormone (SIADH)** induced by sulfonylureas. ## Mechanism of Sulfonylurea-Induced SIADH **Key Point:** Sulfonylureas stimulate ADH (vasopressin) release from the posterior pituitary via: 1. Direct stimulation of hypothalamic neurons 2. Enhanced ADH secretion independent of osmotic triggers 3. Potentiation of ADH action on renal collecting ducts Chloropropamide and tolbutamide are the most notorious offenders; gliclazide and glipizide cause SIADH less frequently. ## Diagnostic Algorithm for Hyponatremia ```mermaid flowchart TD A[Hyponatremia Na+ &lt; 130 mEq/L]:::outcome --> B{Volume Status?}:::decision B -->|Euvolemic| C[Measure serum osmolality]:::action C --> D{Serum osmolality?}:::decision D -->|Low &lt; 280 mOsm/kg| E[SIADH likely]:::outcome E --> F[Measure urine osmolality + urine Na+]:::action F --> G{Urine osmolality &gt; 200 mOsm/kg?}:::decision G -->|Yes + Urine Na+ &gt; 40 mEq/L| H[SIADH confirmed]:::outcome D -->|Normal/High| I[Other causes: adrenal, thyroid, renal]:::outcome ``` ## Diagnostic Criteria for SIADH | Finding | Expected in SIADH | Why | | --- | --- | --- | | **Serum osmolality** | <280 mOsm/kg (hypotonic) | ADH causes water retention without solute | | **Urine osmolality** | >200 mOsm/kg (inappropriately high) | Kidneys concentrating urine despite low serum osmolality | | **Urine sodium** | >40 mEq/L (high) | Euvolemia with normal renal perfusion maintains urinary Na+ excretion | | **Serum Na+** | <130 mEq/L | Dilutional hyponatremia from water retention | | **TSH, cortisol** | Normal | Rules out thyroid and adrenal causes | ## High-Yield Facts **High-Yield:** Sulfonylurea-induced SIADH is: - Most common with **chlorpropamide** (>10% incidence) - Less common with tolbutamide (3–5%) - Rare with newer agents (gliclazide, glipizide, glimepiride) - Reversible within 24–48 hours of drug discontinuation **Clinical Pearl:** The **simultaneous measurement of serum and urine osmolality with urine sodium** is the gold standard diagnostic test for SIADH. It distinguishes SIADH from other causes of euvolemic hyponatremia (hypothyroidism, adrenal insufficiency, polydipsia). **Mnemonic: SIADH Diagnosis** — **SUMO** = **S**erum osmolality (low), **U**rine osmolality (high), **M**easure urine sodium (high), **O**smotic gradient (inverted).